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Systematic reviews and meta-analyses pool data from individual studies to generate a higher level of 
evidence to be evaluated by guidelines. These reviews ultimately guide clinicians and stake-holders in 
health-related decisions. However, the informativeness and quality of evidence synthesis inherently depends 
on the quality of what has been pooled into meta-research projects. Moreover, beyond the quality of included 
individual studies, only a methodologically correct process, in relation to systematic reviews and meta-
analyses themselves, can produce a reliable and valid evidence synthesis. Hence, quality of meta-research 
projects also affect evidence synthesis reliability. In this overview, the authors provide a synthesis of 
advantages and disadvantages, and main characteristics of some of the most frequently used tools to assess 
quality of individual studies, systematic reviews and meta-analyses. Specifically, the tools considered in this 
work are the Newcastle-Ottawa Scale (NOS) and the Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) for observational studies, the Consolidated Standards of Reporting Trials 
(CONSORT), the Jadad scale, the Cochrane risk of bias tool 2(RoB2) for randomized controlled trials, the 
Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) and the Assessment of 






















The quality assessment of individual studies included in meta-research manuscripts represents a 
fundamental step for supporting all the evidence synthetized by meta-research [1,2]. Although meta-research 
is considered the highest scientific level for summarizing the results from different analyses, at the same time 
there are also many potential sources of biases [3-5]. These sources of bias include for instance a potentially 
imprecise selection of subjects, a potentially inaccurate data collection and analysis, and possible biases in 
reporting the results of studies. It should be noted that the majority of potential biases derive directly from 
the manuscripts that are selected for a given meta-research study, hence the assessment of their quality must 
be accurately evaluated, using validated and standardized tools [1,2]. 
 Producing reliable data to support results of scientific research and medical and public health 
decisions is of growing importance, given the huge rise in scientific reports published each year across 
different areas of medicine, and the frequently conflicting results of studies on the same topic. To summarize 
the effectiveness of medical interventions for a disease, and evidence from different studies that is 
conflicting, the only criterion to rank sources of information is the quality of studies, which need to be 
assessed using specific validated instruments [1]. 
This overview aims to serve as a starting point and a brief guide to identify and understand the main 
and most frequently used tools for assessing the quality of studies included in meta-research. The authors 
here share their experience in publishing several meta-research related articles covering different areas of 
medical sciences, including pathology, oncology, psychiatry, internal medicine, geriatrics, sport-exercise 
medicine, cardiology and nutrition.  
The tools that will be discussed in this review include: the Newcastle-Ottawa Scale (NOS) and the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE), for observational studies; 
The Consolidated Standards of Reporting Trials (CONSORT), the Jadad scale, and the Cochrane risk of bias 
tool, for randomized controlled trials; The Preferred Reporting Items for Systematic Reviews and Meta-
analysis (PRISMA), together with the Assessment of Multiple Systematic Reviews 2 and –PLUS 
(AMSTAR2 and AMSTAR-PLUS) for meta-analyses. For each item, a brief description, together with key 
strengths and limitations, will be discussed. Moreover, we provide examples of appropriate use of the 






An observational study draws inferences from a group of subjects where the independent variable is not 
under the control of the researchers because of ethical concerns, operational restrictions or other reasons. In 
our experience, there are two main tools for quality assessment of observational studies, namely the 
“Newcastle-Ottawa Scale” (NOS) and the “Strengthening the Reporting of Observational Studies in 
Epidemiology” (STROBE). 
 
The “Newcastle-Ottawa Scale” (NOS) 
A comprehensive manual and additional information on this scale can be freely downloaded at: 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 
Definition 
The NOS can be used to assess the quality of the observational studies included in a meta-research 
analysis [6-10]. This tool can be used for both case-control and longitudinal (prospective, cohort studies) 
studies [9]. The NOS contains three domains, which are associated with the quality concept. These domains 
include (i) the selection of the participants, (ii) the comparability between cases and controls, and (iii) the 
accuracy of the evaluation of the outcomes. These domains are divided into eight specific items, which 
slightly differ when scoring case control and longitudinal studies [5-10]. Each item on the NOS is typically 
scored one point, except for the comparability item, which can be scored two points, after a specific 
adaptation to topic of interest [10]. Thus, the maximum score for each study is represented by 9 points, with 
studies having less than 5 points being identified as high risk of bias. [9-10] 
Since this process may be subjective (e.g. the choice of the items to be scored is guided above all by 
the expertise of authors), it has been suggested that two independent researchers should score each paper. In 
our opinion, the most important as well as critical point in the NOS scoring relates to the common 
instruments utilized in specific fields in which the meta-analysis has been conducted. For instance, while 
exposure in studies focusing on subjects with acute myocardial infarction have used valid and  objective 
measures, this might not always be the case in studies focusing on subjective constructs such a stress, 
depressive symptoms rated with self-report questionnaires, or with retrospective assessment of past events 
such as maltreatment or abuse.  
Advantages and limitations 
NOS has several advantages. First, NOS can be completed in a short amount of time. Second, it is 
the authors’ view that the scale shows great adaptability to the investigated topic, owing to the versatile 
nature of its indexes. For example, different meta-analyses investigating the prognostic role of the same 
moderator (e.g. extranodal extension of nodal metastasis) in different cancer types can be evaluated adapting 
the NOS to the specific cancer (e.g. 1 point for a follow-up longer than 60 months for tumors with low or 
intermediate malignant behavior, such as thyroid, breast prostate or colorectal cancer [11-13], and 1 point for 
a follow-up longer than 36 months for more aggressive and highly malignant tumors, such as esophageal, 
gastric or pancreatic cancer [11-16]). We believe that this practical model represents an excellent example of 
the NOS adaptability and versatility. Other not-negligible advantages are represented by the final score 
(ranging from 0 to 9), which can be used as a potential moderator in meta-regression analysis (or in 
sensitivity analyses), and its possible application for both case-control and longitudinal studies [9,10]. 
Limitations of the NOS are various and meta-researchers should be aware of these to limit their 
impact during the important process of quality assessment. First, some indices are not univocal, and some 
items need to  be adapted when applying the NOS to  cross-sectional and case-control studies. Second, 
although the adaptability of the indexes represents a point of strength, it can represent another possible 
source of bias. The points usually adapted by the authors are the number and type of adjustments in the 
multivariate analyses (if present), the duration of follow-up (as already discussed in the section of points of 
strength) and the outcome of interest not present at the baseline. Another potential limitation, in our opinion, 
is the suboptimal agreement that can be encountered between two independent reviewers in completing the 
NOS. Finally, it is not possible to apply NOS to cross-sectional studies that, however, are often included in 
meta-research. 
Concluding remarks 
The versatility of the NOS and its wide applicability are the most important advantages for using this 
quality assessment tool in meta-research. The correct interpretation and decision of the parameters to be 
listed and analyzed for the different indexes (e.g. 5 year of follow-up for prostate cancer and only 3 for the 
highly malignant pancreatic cancer), at least in our opinion, should be ensured through a complete 
knowledge of the topic analyzed within a meta-research, and the potential low agreement between coauthors 
in completing the NOS scale can be overcome through a final consensus, involving at least one additional 
expert coauthor. 
 
The “Strengthening the Reporting of Observational Studies in Epidemiology” (STROBE)  
A comprehensive manual and the downloadable form of STROBE checklist can be found at: 
https://www.strobe-statement.org/index.php?id=available-checklists. 
Definition 
STROBE  is another tool that assists researchers in the fundamental step of quality assessment. It consists of 
a checklist of 22 items, which relate to the manuscript’s title/abstract (1 item), introduction (2 items), 
methods (9 items), results (5 items), discussion (4 items) and findings (1 items) [17]. Eighteen items relate to 
cohort studies, case-control studies and cross-sectional studies, whereas four are specific to each of the three 
study designs. STROBE provides general reporting recommendations for descriptive observational studies 
and studies that investigate associations between exposures and health outcomes [17,18]. STROBE addresses 
the three main types of observational studies: cohort, case-control and cross-sectional studies. Recently, for 
improving scientific reporting in nutritional epidemiological studies, a new tool called STROBE-nut 
(STrengthening the Reporting of Observational Studies in Epidemiology-nutritional epidemiology) 
(STROBE-nut) has been designed [19]. This statement comprises a set of 24 items, organized as a checklist, 
with the aim to ensure that all information is available, to enable quality appraisal, correct understanding, 
effective replication and application of findings. This tool can enhance the quality of the nutritional 
epidemiology field output. The additional items have been specifically designed for topics regarding 
nutrition-related issues and represent the direct demonstration of the adaptability of STROBE  to different 
types of research areas. 
 
Advantages and limitations 
STROBE recommendations aim at explaining how to report research and provides detailed 
explanations for each checklist item [17-20]. STROBE  may also aid in planning observational studies, and 
guide peer-reviewers and editors in their evaluation of manuscripts [17-20] 
 
A key limitation of STROBE is that it does not  specifically address topics such as genetic linkage 
studies, infectious disease modelling or case reports and case series. Thus, STROBE should be avoided for 
observational studies that specifically investigate diagnostic tests, tumor biomarkers and genetic associations. 
A recent paper has also highlighted that the endorsement of STROBE by journals is key to authors' 
awareness and adherence of the STROBE guideline [21]. Also, ambiguity in the language can affect 
STROBE reliability [22]. 
Concluding remarks 
STROBE is not applicable to all possible observational studies. Therefore, authors carrying out 
meta-research must carefully consider its use to avoid incorrect choice of this item. At the same time, where 
applicable, it is a  reliable and reproducible tool for assessing the quality of observational papers in meta-
research. In our opinion, STROBE is a useful tool for double-checking if all the points required by an 
observational study are included in the manuscript. Unambiguous language is desirable to increase adherence 




RANDOMIZED CONTROLLED TRIALS 
 
A randomized controlled trial (RCT) is a scientific experiment aiming at reducing potential sources of bias 
when testing the effectiveness of new treatments; this is accomplished by randomly allocating subjects to 
two or more groups, treating them differently, and then comparing the different treatments with respect to a 
measured response. Among others, three tools are frequently used in the quality assessment of randomized 
controlled trials in meta-research. They are: the “Consolidated Standards of Reporting Trials”, the “Jadad 
scale”, and the “Cochrane-risk of bias” tool 2 (RoB2). 
 
The “Consolidated Standards of Reporting Trials” (CONSORT) 
A comprehensive manual with additional information (to that discussed here) and the downloadable form of 
the CONSORT checklist can be found at http://www.consort-statement.org/. 
Definition 
CONSORT consists of a checklist of fundamental items that should be included in reports of randomized 
controlled trials and a diagram for documenting the flow of participants through a trial [23]. CONSORT can 
be adapted to a wider class of trial designs, such as equivalence, factorial, cluster, crossover and non-
inferiority trials [23]. The main aim of the CONSORT is to furnish basic guidelines to authors for improving 
and enlightening the reports of RCTs. Indeed, they must be clear, complete and transparent, since all readers, 
peer reviewers and editors can also use CONSORT, to help them in critically appraising and interpreting 
reports of RCTs [23,24].  
 CONSORT has been extended recently to enhance the reporting of randomized adaptive-design 
clinical trials [24[. An Adaptive designs CONSORT Extension (so-called “ACE”) guideline was developed, 
with the intention of enhancing transparency and improving the report of adaptive-design randomized trials, 
to increase both the interpretability of their results and reproducibility of their methods, results and inference 
[25]. 
 
Advantages and limitations 
CONSORT represents an excellent instrument for ensuring, but also for clearly evaluating, the 
quality of RCTs. 
The main limitation of CONSORT regards its initial design. Indeed, CONSORT was not designed n 
to be used as a quality assessment instrument [23-28]. Conversely, the content of CONSORT focuses on 
items specifically associated to the internal and external validity of trials. Several items not explicitly taken 
into account by CONSORT should also be cited in a report, such as information about ethical approval 
(including guidelines stated in the Declaration of Helsinki 1964 and subsequent amendments, and ethical 
committee approval), obtaining informed consent from participants, and, where relevant, existence of a data 
safety and monitoring committee [27]. In addition, any other aspects of a trial that are mentioned should be 
accurately described, as for example information regarding cost/effectiveness analysis. 
Concluding remarks 
CONSORT was not specifically conceived as an instrument for quality assessment; its content and 
application, however, is fundamental in meta-research papers investigating randomized controlled trials. This 
tool is continuously evolving  in relation to covering new aspects of randomized controlled trials. Our 
recommendation is that authors of meta-research regularly review the literature around this topic to inform 
their effective implementation of the tool 
 
The Jadad Scale 
The seminal paper that  introduced the Jadad scale was published in 1996 in Control Clin Trials [4]. 
Definition 
Jadad scale is composed of three questions, with binary yes/no answers. The first question focuses on 
randomization, the second on double-blinding, the third on whether the study reported all information on 
non-completers. In addition to the three points given by a yes answer to the above three questions, two 
additional points can be obtained if authors described in detail a correct procedure for randomization, and for 
blinding. The maximum score of the Jadad scale is five. 
Advantages and limitations 
Based on our experience, the main advantage of Jadad scale is the short amount of time needed to complete 
it while still assessing main sources of bias. The main disadvantage of the tool is it neglects some key 
information on potential confounding factors affecting the validity of  findings, such as allocation 
concealment, industry sponsorship, and conflict of interest.  Moreover, the Jadad scale bases its score only 
on a few questions (which is also its advantage), without a clearer framework to be used as reference, and 
without more specific questions, and so can generate somewhat subjective ratings, at least compared to more 
comprehensive tools such a s RoB 2 ( see below). 
Concluding remarks 
Jadad scale is a valid tool to initially rate the quality of an RCT, in a short amount of time. Jadad is a valid 
instrument for use when assessing RCTs. However, it predominantly provides a broad assessment. 
Therefore, other instruments have been developed to provide a more detailed assessment of RCTs. Indeed, 
its accuracy and precision are to date inferior compared with other more exhaustive updated instruments (see 
below).  
 
The Cochrane Risk of Bias Tool 2 (RoB2) 
The full manual and rationale behind the Cochrane Risk of Bias Tool 2 (RoB2) [29,30], together with video 
tutorials explaining how to score each item of the tool, as well as a Microsoft Excel sheet to score RoB2 can 
be found at: https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool?authuser=0. Version 2 of 
this tool replaces the first version, originally published in 2008, and updated in 2011 [31].  
Definition 
The RoB2 tool assesses five domains, namely (1) risk of bias arising from randomization process, (2) risk of 
bias due to adherence or assignment to the intended intervention, (3) risk of bias due to missing outcome 
data, (4) risk of bias in measurement of outcome, (5) risk of bias in the selection of reported results.  Each 
domain needs to be assessed by several questions: Three questions are asked for the randomization domain 
relating to (i) random sequence generation, (ii) allocation concealed until participants enrolled, and (iii) 
difference in baseline values. Seven questions are asked for the adherence  or assignment to intervention 
domain relating to  (i) participants blinding, (ii) person delivering treatment blinding, (iii) deviations from 
intended treatment (iv) type of analysis accounting for group assignment, and  (v) potential errors in 
assigning an individual’s results to the wrong group., Three questions are asked for the bias due to missing 
outcome data domain relating to  (i) data available for almost all randomized subjects, (ii) result not biased 
by missing data, (iii) possibility or likeliness of missingness of outcome is related to the outcome’s nature. 
Five questions are asked for the assessing bias in outcome assessment domain relating to  (i) method of 
outcome measurement, (ii) difference in outcome assessment between groups, (iii) outcome assessor 
blinding, and (iv) blinding of participants.) Three questions are asked for the assessing bias in results 
selective reporting domain relating to (i)a-priori protocol, (ii) the presence of one or more measures to assess 
outcome, and (iii) the presence of one or more analyses to assess outcome. Each domain is rated as having a 
low risk of bias, as having some concerns suggesting bias, or as having a high risk of bias. Finally, an overall 
judgement of the risk of bias of a given RCT is provided, with a low risk of bias if low risk of bias is 
measured in all domains, some concerns if some concerns are measured in at least one domain, and high risk 
of bias if high risk of bias is measured in at least one domain.  
Advantages and limitations 
RoB2 form the Cochrane group is to our knowledge the most updated, reliable, valid, and comprehensive 
tool to assess potential biases in RCTs. Clear instructions are provided, together with instruments to be used 
to rate RoB2. Of course, such an exhaustive instrument takes significant time to rate one single RCT (which 
could be the only disadvantage compared with Jadad). However, we believe RoB2 largely outperforms Jadad 
methods, and should be considered as the gold-standard to rate RCTs quality. 
Concluding remarks 
RoB2 is the gold-standard instrument to evaluate the quality and presence of bias in RCTs. We recommend 
researchers take the necessary time to become confident with the instrument and given its complexity two 
blinded raters should  score  in parallel. RoB2 scored in double-blind should be the first choice for any high-





Meta-analyses are meta-research projects which pool data from previously published individual studies, and 
provide a pooled estimate of the association investigated in original included studies. A meta-analysis 
accounts for within and between studies heterogeneity, and for random-error, when a random-effect model  
is chosen in analyses [32]. A meta-analysis also provides a heterogeneity index, which can be considered as a 
proxy of underlying factors which influence the effect size of individual studies. One of these factors that 
most frequently influence the magnitude of an effect size is the quality of studies included in a meta-analysis.  
 
Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 
A full manual and rationale to use PRISMA are available at http://www.prisma-statement.org/. PRISMA has 
been published in different journals, for instance in BMJ [33]. 
Definition 
PRISMA works as a checklist to guide authors in correct reporting of all needed details for  high quality 
reporting in systematic reviews and meta-analyses. PRISMA assesses the quality of reporting, not of the 
method used in the meta-analysis, neither on the quality of included studies. Similar, to the STROBE 
checklist, the PRISMA requests authors to report a title, a structured summary, rationale and objectives in the 
introduction. In the methods, authors must indicate at what page they provided information on protocol and 
its registration, eligibility criteria, information sources, search, study selection procedure, data collection 
process, data items when extracting data, risk of bias in individual studies, summary measures, synthesis of 
results, risk of bias across studies, and eventual additional analyses. In the results section authors must 
indicate study selection results (PRISMA flowchart), study characteristics, risk of bias within studies, results 
of individual studies, synthesis of results, risk of bias across studies, additional analyses. In the discussion, 
where they indicate summary of evidence, they must also indicate limitations and conclusions. Finally, 
PRISMA requests authors to disclose any sources of funding within the manuscript. For each of the above 
items of the checklist, authors must indicate at what page they reported the information. 
Advantages and limitations. 
Following the PRISMA statement it is a necessary step to provide high quality reporting in any systematic 
review or meta-analysis. We strongly suggest adhering to PRISMA statement for any meta-research process 
and in particular to use the PRISMA figure, which is the standardized optimal instrument to represent the 
flow-chart of study selection process. 
Concluding remarks 
PRISMA statement should be used as a guide when preparing a meta-research project, starting from its 
protocol. Also, it can be considered a measure of the quality in reporting of the meta-research project. 
However, it should not be used as an instrument for the quality assessment of a meta-analysis. Another point 
to be added, at least in our opinion, regards the use of different databases for meta-analysis, although it is not 
mandatory for PRISMA. For example,, it may be of importance to use  different databases (e.g. Pubmed, 
SCOPUS, Embase) to improve the overall quality and to expand the possibilities of finding all potentially 
useful references. 
The Assessment of Multiple Systematic Reviews2 (AMSTAR2) 
AMSTAR was first developed and launched in 2007. Starting from an initial 37 items, an exploratory factor 
analysis was used to identify underlying components producing 11 constructs that now make up the 
AMSTAR [34]. AMSTAR2 [35] is an updated and improved version of the AMSTAR [34,36,37], which is 
available at: https://amstar.ca/index.php , where it can be scored on-line. Of importance, AMSTAR2 has 16 
items in total (compared to the 11 original), has simple categorization and indication for each domain, and 
has an overall rating scale (critically low to high), contrary to the original version.  
Definition 
AMSTAR2 is composed of 16 questions. The questions focus on whether authors considered PICO 
(Population Intervention Comparison Outcome) for inclusion criteria, if there was an “a-priori” protocol, if 
the reason to include one study design only was provided, if a comprehensive literature search was run (at 
least two databases searched), if study selection and data extraction were performed in duplicate, if a list of 
both included and excluded studies (after full-text assessment) was provided, if included studies are 
described in adequate detail, if authors assessed the risk of bias of included studies, if source of funding was 
stated, if statistical analyses were correct, if authors considered the impact of the risk of bias in the meta-
analysis and when interpreting results, if authors explained heterogeneous results, if authors assessed and 
discussed publication bias, and finally if conflict of interest was disclosed. After answering the 16 questions 
of AMSTAR2 on the on-line platform, the quality (namely the confidence in results) is rated into either high, 
moderate, low, critically low.  
Advantages and limitations 
AMSTAR2 is a valid instrument to assess the methodological quality of meta-analyses and can be easily 
scored on a dedicated platform which also calculates the quality category; this instrument has been validated 
and is already widely used and deemed reliable by the scientific community. AMSTAR2 is not intended to 
generate an overall score. However, as also emerged by our experience, a disadvantage of the AMSTAR2 is 
that it does not really provide information beyond the methodological quality of the meta-analysis, and 
specifically on the studies included in the meta-analysis. 
Concluding remarks 
AMSTAR 2 is a validated tool that should be used to score the methodological quality of meta-analyses. 
However, to also gain some insight into the quality of studies included in the meta-analysis, and hence in the 
validity of a meta-analysis results, other instruments should be used. 
 
The Assessment of Multiple Systematic Reviews-PLUS (AMSTAR-PLUS) 
AMSTAR-PLUS has been proposed in a recent overview of meta-analysis to score the quality of both the 
methods of the meta-analysis, and its content [38].  
Definition 
AMSTAR-PLUS is composed of 16 items. The first 11 items are those of the AMSTAR. Authors have then 
supplemented AMSTAR with AMSTAR-PLUS items, which ask whether the majority of studies were 
double-blinded RCTs, if the total number of participants was sufficiently large, if the pooled effect size was 
confirmed in the largest individual study, if observed cases analyses were performed, if the outcome was 
heterogeneous, and if there was publication bias. 
Advantages and limitations  
Differently from AMSTAR2, to our knowledge AMSTAR-PLUS has not undergone rigorous validation and 
standardization. However, we believe that it adds information on the content of a meta-analysis, which is  
crucial information that cannot be neglected when measuring credibility of results from a  meta-analysis. For 
instance, technically accurate meta-analyses can be performed, but they may include low quality studies, 
heterogeneous results, affected by publication bias, based on small studies, and so on. Hence, we believe 
that, AMSTAR-PLUS might be the first choice when assessing the quality of meta-analyses including RCTs. 
Concluding remarks 
AMSTAR-PLUS merges the insight on the methodological process of a meta-analysis with its first eleven 
questions, and in addition to this also provides an insight into the quality of studies included in a meta-
analysis. AMSTAR-PLUS total score can be considered a s a single score, or it can split into the 
methodological scores (first eleven questions), and the “Content” score (last six questions). 
 
CONCLUSIONS 
In this review, we have reported and summarized the most commonly used tools for assessing 
quality in observational and intervention studies as well as in meta-analyses. Overall, all these tools have 
important advantages and disadvantages.  
When performing an individual study or a meta-research project, STROBE, CONSORT, and 
PRISMA check-lists should always guide the protocol draft and the reporting in publications. In 
observational studies, a brief instrument such as the NOS scale merges accuracy and time needed to score the 
instrument, and should be considered as a first-option when assessing the quality of observational studies in 
meta-research. When assessing quality of RCTs, RoB2 should be considered as the first option. When 
assessing meta-analyses quality, AMSTAR2 should be used if one is only interested in methodological 
quality of a meta-analysis, but AMSTAR-PLUS should be used when one is also interested in the quality of 
the meta-analysis’ content. 
Another important aspect is the plasticity of these tools. Ideally, we would like to have only one tool for 
assessing all kinds of observational studies, and only one for assessing the quality/risk of bias of intervention 
studies. For example, we do not have any specific tool for open-label trials or non-controlled trials that are, 
on the contrary, of importance in certain disciplines such as psychiatry or geriatrics. Future research should 
aim to develop such tools and in the meantime researchers should utilize this overview to inform the most 
appropriate tool(s) to use for their meta-research projects.    
HIGHLIGHTS 
What is already known:  
The informativeness and quality of evidence synthesis inherently depends on the quality of what has been 
pooled into meta-research projects. Beyond the quality of included individual studies, only a 
methodologically correct process, in relation to systematic reviews and meta-analyses themselves, can 
produce a reliable and valid evidence synthesis. 
What is new: 
In this overview, the authors provide a synthesis of advantages and disadvantages, and main characteristics 
of some of the most frequently used tools  to assess quality of individual studies, systematic reviews and 
meta-analyses. 
Potential Impact: 
This overview serves as a starting point and a brief guide to identify and understand the main and most 
frequently used tools for assessing the quality of studies included in meta-research. The authors here share 
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Table 1. Characteristics of the quality assessment instruments considered in this overview. 
 
 
Instrument For which studies Main aim of the instrument Structure of instrument Quality measure 
categories 
Main advantage Main disadvantage Cut-off for high quality 
NOS Observational Scale 8 questions for a maximum 
score of 9 – 
One star (*) for each item, 
except from comparability, 




Plasticity / Adaptability. 
Not time consuming. 
Potential subjectivity in 
defining and scoring items 
A score of at least 6 equals no 
high risk of bias 
STROBE  Observational Checklist 22 items Not applicable It’s a guide for both 
protocol drafting, and 
results reporting. 
Does not cover all possible 
observational studies (e.g. 
diagnostic tests, genetic 
associations) 
Not applicable 
CONSORT Randomized controlled trials Checklist 25 questions Not applicable It’s a guide for both 
protocol drafting, and 
results reporting. 
Some items not included, 
originally not a quality tool 
Not applicable 
RoB2 Randomized controlled trials Assess the presence of bias Five domains – several 
questions within each domain. 
Low risk of bias 
Some concerns 
High risk of bias 
Validated, reliable, 
comprehensive and fruible 
documentation to learn to 
use it. 
Time consuming See categories 
JADAD Randomized controlled trials Assess the presence of bias 5 questions “yes”/”no” Continuous score. 
Range 0-5 
Valid for rough evaluation. 
Not time consuming. 
Neglects some important 
sources of bias 
> 3/5 
PRISMA Meta-analyses Guide and assess the quality of 
reporting 
27 questions Not applicable It’s a guide for both 
protocol drafting, and 
results reporting. 
Some items not included, 
originally not a quality tool 
Not applicable 
AMSTAR2 Meta-analyses Assess the methodological 
quality 
16 items High quality, moderate 
quality, low quality, 
critically low quality. 
 
Validated instrument, 
online platform for scoring. 
Does not provide information 
on the meta-analysis content. 
See categories 
AMSTAR-PLUS Meta-analyses Assesse both methodological 
quality, and content’s quality 
17 items Continuous score 0 to 
20. Two subscores for 
AMSTAR (1 to 11), 
and PLUS-Content (o to 
9) 
Assess both 
methodological quality and 
quality of included studies. 
Continuous score has been 
used as moderator in meta-
regression. 
Not validated. None proposed to date. 
